Cooper Companies Reports Q3 Results on September 9

The Cooper Companies is scheduled to announce its fiscal third-quarter 2026 financial results on September 9, after the market close. According to data from GN markets/earnings (en-US), the consensus estimate for total sales is set at $1.1 billion, representing a 3.6% increase year over year. The expected bottom line stands at $1.11 per share, indicating a slight 0.9% growth compared to the prior year period.

Analyst estimates have remained stable over the past week, suggesting no significant shifts in market expectations. The company has a recent history of outperforming these figures, having beaten earnings estimates in each of the last four quarters with an average surprise of 5.8%. However, current modeling tools do not strongly predict another beat this time, as the Earnings ESP metric sits at 0.00% and the stock carries a sell rank.

Operational Drivers in Vision and Surgery

The CooperVision segment is expected to remain the primary growth engine for the quarter. Revenue growth should be supported by strong demand for premium daily silicone hydrogel lenses in the Americas and EMEA regions. The MyDay portfolio, including multifocal and Energys lines, is credited for gaining traction through expanded customer partnerships and branded contract wins, while Biofinity toric and multifocal lenses also contribute meaningfully to sales.

Myopia control products continue to serve as a significant growth contributor. The MiSight product line delivered 24% growth in the previous quarter, driven by momentum in Japan and increasing adoption of MyDay MiSight in Europe. Although spectacle-based competitors create near-term pressure, favorable clinician reception and ongoing product launches support long-term adoption trends.

Fertility Trends and Regional Headwinds

Within the CooperSurgical division, fertility trends are expected to remain favorable as IVF market conditions improve across key markets. Management anticipates the fertility business will return to mid-single-digit growth in the second half of the year, following a strong prior quarter that benefited from capital equipment sales and temporary distributor restocking in the Middle East. Demand for genomics, consumables, and Witness laboratory tracking systems also supports quarterly performance.

Regional performance is mixed, with the Americas and EMEA maintaining healthy growth trajectories. In contrast, Asia Pacific remains a significant headwind due to persistent consumer weakness in Japan and China. Management has guided for another quarterly decline in this region, citing the continued rationalization of legacy hydrogel products and broader macroeconomic challenges.

Guidance Maintained Despite Macro Headwinds

Management maintained its fiscal 2026 adjusted EPS guidance of $4.58 to $4.66 following a strong second quarter. This decision reflects confidence in the company's execution capabilities despite ongoing macroeconomic headwinds in the Asia Pacific region. The consistent guidance signals that the business remains on track to meet its annual targets, supported by operational efficiency initiatives and robust demand in core markets.